ASSOCIATIONS

■ The American Academy of Optometry will recognize Martin S. Banks, M.A., Ph.D. with the Charles F. Prentice Medal and Lecture Award, as well as several others at its annual meeting Nov. 9 to Nov. 12. For more, visit aaopt.org.

■ The Vision Council announced Ashley Mills as its new CEO following the retirement of industry veteran Mike Daley, previously announced in June.

COMPANY NEWS

■ ABB Optical Group has launched a newly designed website. Visit ABBOptical.com to view it. In other news, Primary Eyecare Network, a division of ABB, is hosting the following webinars: Worker’s Compensation on Nov. 16; and Jump Start the Medical Side of Your Practice on Dec. 7. Visit PrimaryEye.net.

■ Acuity Pro has included the Acuity Pro logo and the OGS logo on a beach chair caddy, which will be available for $5 on AcuityPro.com. A portion of every chair sold goes directly to Optometry Giving Sight.

■ The FDA has issued a clearance for NIDEK’s MP-3 Microperimeter. It is now available in the United States. Visit Nidek.com.

■ Optometry Giving Sight announced that CooperVision has renewed its commitment as a Global Gold Sponsor for another three years, effective January 2017.

■ Katena Products, a global provider of ophthalmic instruments, biologics and devices, announced the purchase of Eagle Vision, a provider of dry eye products.

■ RevolutionEHR has acquired Getwell. Users of Getwell, Visions and Eyebase software will see a transition to RevolutionEHR in their practices. Visit revolutionehr.com.

■ Andrew Ihan Chang will lead Carl Zeiss Meditec’s strategic business unit for global ophthalmic devices, comprised of surgical ophthalmology, ophthalmic diagnostics and refractive lasers. In other news, the company appointed Steven C. Schallhorn, M.D., as chief medical officer for the unit. Dr. Schallhorn will provide strategic direction for the business and medical guidance on the clinical use of Zeiss’ portfolio.

MEDICAL

■ Roclatan, from Aerie Pharmaceuticals, achieved its primary efficacy endpoint in a Phase 3 clinical trial of the fixed-dose combination drug candidate for the treatment of glaucoma.

■ At press time, Allergan announced the FDA had approved Restasis Multidose (cyclosporine ophthalmic solution) 0.05%, a preservative-free, multi-dose bottle that offers the same preservative-free formulation of Restasis that was approved in 2003. The newly-approved Multidose is designed with a unidirectional valve and air filter technology that eliminates the need for a preservative. The new multidose bottle uses less plastic than a package of single use vials and will be available for the same price. OM